222 related articles for article (PubMed ID: 14581343)
21. Methylated genes as potential biomarkers in prostate cancer.
Phé V; Cussenot O; Rouprêt M
BJU Int; 2010 May; 105(10):1364-70. PubMed ID: 20067451
[TBL] [Abstract][Full Text] [Related]
22. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines.
Harada K; Toyooka S; Maitra A; Maruyama R; Toyooka KO; Timmons CF; Tomlinson GE; Mastrangelo D; Hay RJ; Minna JD; Gazdar AF
Oncogene; 2002 Jun; 21(27):4345-9. PubMed ID: 12082624
[TBL] [Abstract][Full Text] [Related]
23. Promoter hypermethylation of multiple genes in early gastric adenocarcinoma and precancerous lesions.
Zou XP; Zhang B; Zhang XQ; Chen M; Cao J; Liu WJ
Hum Pathol; 2009 Nov; 40(11):1534-42. PubMed ID: 19695681
[TBL] [Abstract][Full Text] [Related]
24. Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage.
Rouprêt M; Hupertan V; Yates DR; Catto JW; Rehman I; Meuth M; Ricci S; Lacave R; Cancel-Tassin G; de la Taille A; Rozet F; Cathelineau X; Vallancien G; Hamdy FC; Cussenot O
Clin Cancer Res; 2007 Mar; 13(6):1720-5. PubMed ID: 17363525
[TBL] [Abstract][Full Text] [Related]
25. Frequent hypermethylation of the RASSF1A gene in prostate cancer.
Liu L; Yoon JH; Dammann R; Pfeifer GP
Oncogene; 2002 Oct; 21(44):6835-40. PubMed ID: 12360410
[TBL] [Abstract][Full Text] [Related]
26. Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene.
Zhang J; Liu L; Pfeifer GP
Oncogene; 2004 Mar; 23(12):2241-9. PubMed ID: 14691453
[TBL] [Abstract][Full Text] [Related]
27. Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features.
Cho NY; Kim BH; Choi M; Yoo EJ; Moon KC; Cho YM; Kim D; Kang GH
J Pathol; 2007 Feb; 211(3):269-77. PubMed ID: 17139617
[TBL] [Abstract][Full Text] [Related]
28. Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma.
Enokida H; Shiina H; Urakami S; Terashima M; Ogishima T; Li LC; Kawahara M; Nakagawa M; Kane CJ; Carroll PR; Igawa M; Dahiya R
Cancer; 2006 Jan; 106(1):79-86. PubMed ID: 16323173
[TBL] [Abstract][Full Text] [Related]
29. Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer.
Hoque MO; Begum S; Topaloglu O; Jeronimo C; Mambo E; Westra WH; Califano JA; Sidransky D
Cancer Res; 2004 Aug; 64(15):5511-7. PubMed ID: 15289362
[TBL] [Abstract][Full Text] [Related]
30. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features.
Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY
Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794
[TBL] [Abstract][Full Text] [Related]
31. Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis.
Takahashi T; Shivapurkar N; Riquelme E; Shigematsu H; Reddy J; Suzuki M; Miyajima K; Zhou X; Bekele BN; Gazdar AF; Wistuba II
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6126-33. PubMed ID: 15447999
[TBL] [Abstract][Full Text] [Related]
32. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
33. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features.
Lin SY; Yeh KT; Chen WT; Chen HC; Chen ST; Chiou HY; Chang JG
Oncol Rep; 2004 Feb; 11(2):341-8. PubMed ID: 14719065
[TBL] [Abstract][Full Text] [Related]
34. HRK inactivation associated with promoter methylation and LOH in prostate cancer.
Higuchi T; Nakamura M; Shimada K; Ishida E; Hirao K; Konishi N
Prostate; 2008 Jan; 68(1):105-13. PubMed ID: 18008329
[TBL] [Abstract][Full Text] [Related]
35. Gene promoter methylation in prostate tumor-associated stromal cells.
Hanson JA; Gillespie JW; Grover A; Tangrea MA; Chuaqui RF; Emmert-Buck MR; Tangrea JA; Libutti SK; Linehan WM; Woodson KG
J Natl Cancer Inst; 2006 Feb; 98(4):255-61. PubMed ID: 16478744
[TBL] [Abstract][Full Text] [Related]
36. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
37. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
[TBL] [Abstract][Full Text] [Related]
38. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
39. Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer.
Asatiani E; Huang WX; Wang A; Rodriguez Ortner E; Cavalli LR; Haddad BR; Gelmann EP
Cancer Res; 2005 Feb; 65(4):1164-73. PubMed ID: 15734999
[TBL] [Abstract][Full Text] [Related]
40. Promoter methylation of RASSF1A, RARbeta and DAPK predict poor prognosis of patients with malignant mesothelioma.
Fischer JR; Ohnmacht U; Rieger N; Zemaitis M; Stoffregen C; Kostrzewa M; Buchholz E; Manegold C; Lahm H
Lung Cancer; 2006 Oct; 54(1):109-16. PubMed ID: 16893590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
